Fig. 5From: Muramyl dipeptide-mediated immunomodulation on monocyte subsets exerts therapeutic effects in a mouse model of Alzheimer’s diseaseA scheme summarizing MDP-mediated immunomodulatory effects on the APP mouse model of AD via converting inflammatory monocytes into patrolling monocytes. MDP treatments improved cognitive declines and Aβ clearance in APP mice and increased expression levels of PSD95 and LRP1 receptorsBack to article page